Topics

Cyclin Dependent Kinase 4 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

15:22 EST 31 Jan 2020 | BioPortfolio Reports

Cyclin Dependent Kinase 4 Pipeline Review, H2 2019


Summary


Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 Cyclindependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thrkinase component of cyclin DCDK4 DC complexes phosphorylate and inhibit members of the retinoblastoma RB protein family including RB1 and regulate the cellcycle during G1/S transition. Activation of the cyclinDCDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.


Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 7, 3, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology which include indications Breast Cancer, NonSmall Cell Lung Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Solid Tumor, TripleNegative Breast Cancer TNBC, Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Colon Cancer, Dedifferentiated Liposarcoma, Epithelial Ovarian Cancer, Esophageal Cancer, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Leukemia, Liposarcoma, Lymphoma, Metastatic Hepatocellular Carcinoma HCC, Metastatic Melanoma, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Prostate Cancer, Recurrent Glioblastoma Multiforme GBM, Thymic Carcinoma, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenocarcinoma Of The Gastroesophageal Junction, AIDS Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer Cholangiocarcinoma, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia CLL, Diffuse Large BCell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, EpsteinBarr Virus HHV4 Infections, Esophageal Squamous Cell Carcinoma ESCC, Ewing Sarcoma, Follicular Lymphoma, Glioblastoma Multiforme GBM, Head And Neck Cancer, HighGrade Glioma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus HIV Infections AIDS, Kidney Cancer Renal Cell Cancer, Lung Cancer, Malignant Mesothelioma, Marginal Zone Bcell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma Kahler Disease, Nonmelanomatous Skin Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia CLL, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia CLL, Relapsed Multiple Myeloma, Rhabdomyosarcoma, SmallCell Lung Cancer, Squamous NonSmall Cell Lung Cancer, Thymoma Thymic Epithelial Tumor, Transitional Cell Cancer Urothelial Cell Cancer, Type 2 Diabetes and Well Differentiated Liposarcoma.


The latest report Cyclin Dependent Kinase 4 Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22

The report reviews Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Cyclin Dependent Kinase 4 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Cyclin Dependent Kinase 4 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...